Emil D. Kakkis is Chief Medical Officer at BIOMARIN PHARMACEUTICAL INC (BMRN). They have made 32 open-market trades across 2 companies since 2006, most recently 2026-04-16.
CIK 0001248093
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
5 open-market purchases totalling $1.1M since 2006, against 27 sales. Across 5 scored buys the stock is down 1.9% at ninety days, and 4.2 points behind the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| RARE | 735,739 | $10.7M |
| BMRN | 47,518 | $2.6M |
| Total | $13.3M |
Shares reported on the most recent Form 4, priced at the 2026-04-20 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 20% | 60% | 60% |
| Avg Move | -12.2% | +0.6% | -1.9% |
| Alpha | -8.9% | +0.3% | -4.2% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RARE | SELL | 2026-03-02 | 2026-03-03 | $22.80 | $1.2M | -3.3% | +1.7% | +3.6% |
| RARE | SELL | 2025-02-28 | 2025-03-04 | $42.16 | $7.2M | -4.0% | -14.3% | -11.9% |
| RARE | SELL | 2024-12-30 | 2024-12-31 | $42.23 | $990K | -5.3% | +2.7% | -14.3% |
| RARE | SELL · 10b5-1 | 2024-12-10 | 2024-12-11 | $50.00 | $414K | -9.8% | -13.5% | -21.1% |
| RARE | SELL · 10b5-1 | 2024-09-03 | 2024-09-05 | $55.85 | $1.1M | +3.4% | -7.3% | -16.7% |
| RARE | SELL · 10b5-1 | 2024-08-06 | 2024-08-07 | $50.17 | $1.0M | +8.3% | +11.2% | +5.1% |
| RARE | SELL | 2024-02-07 | 2024-02-08 | $45.00 | $1.4M | +6.5% | +7.3% | -8.1% |
| RARE | SELL | 2023-12-29 | 2024-01-02 | $47.87 | $1.4M | -4.2% | -7.5% | -1.5% |
| RARE | SELL | 2023-10-19 | 2023-10-23 | $33.52 | $3.2M | +15.3% | +20.4% | +40.6% |
| RARE | SELL | 2022-12-30 | 2023-01-03 | $45.57 | $1.8M | -5.0% | +3.3% | -11.7% |
| RARE | SELL | 2021-05-03 | 2021-05-05 | $107.80 | $3.2M | -4.5% | -20.1% | -27.4% |
| RARE | SELL | 2021-03-01 | 2021-03-03 | $141.80 | $4.3M | +3.2% | -9.5% | -20.3% |
| RARE | SELL | 2021-01-04 | 2021-01-05 | $136.90 | $4.1M | +3.2% | +15.9% | -15.2% |
| RARE | SELL | 2020-11-02 | 2020-11-04 | $96.82 | $2.9M | +4.9% | +13.6% | +35.3% |
| RARE | SELL | 2020-09-01 | 2020-09-02 | $82.63 | $2.5M | +1.1% | +5.1% | +46.2% |
| RARE | SELL | 2020-07-13 | 2020-07-15 | $85.35 | $3.4M | -3.5% | +0.8% | +15.3% |
| RARE | BUY | 2019-09-11 | 2019-09-11 | $43.63 | $218K | +1.6% | -1.7% | -2.3% |
| RARE | SELL | 2019-03-05 | 2019-04-17 | $65.52 | $379K | +1.9% | -5.1% | -8.6% |
| RARE | BUY | 2017-08-28 | 2017-08-29 | $52.52 | $788K | -8.1% | -1.7% | -13.6% |
| RARE | SELL | 2016-11-15 | 2016-11-17 | $81.28 | $3.2M | -3.6% | -12.1% | -5.4% |
| RARE | SELL | 2016-10-14 | 2016-10-18 | $62.84 | $1.1M | +0.5% | +30.7% | +11.1% |
| RARE | SELL | 2016-10-14 | 2016-10-18 | $63.02 | $1.3M | +0.5% | +30.7% | +11.1% |
| RARE | SELL | 2016-08-15 | 2016-08-17 | $67.61 | $1.4M | -0.2% | +18.4% | +25.0% |
| RARE | SELL | 2016-08-15 | 2016-08-17 | $67.61 | $1.4M | -0.2% | +18.4% | +25.0% |
| RARE | SELL | 2016-07-15 | 2016-07-19 | $50.75 | $1.7M | +24.6% | +29.6% | +19.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.